Overview

Prasterone (DHEA) for the Treatment of Hypoactive Sexual Desire Disorder (HSDD) - Second Study

Status:
Withdrawn

Trial end date:
2019-12-06

Target enrollment:

Participant gender:

Summary

The primary objective is to confirm the efficacy of intravaginal prasterone (DHEA) on Hypoactive Sexual Desire Disorder (HSDD) in postmenopausal women.

Phase:

Phase 3

Details

Lead Sponsor:

EndoCeutics Inc.

Collaborator:

AMAG Pharmaceuticals, Inc.

Treatments:

Dehydroepiandrosterone